Enterprise Value to EBITDA Ratio: Champions Oncology Corp (CSBR)

Champions Oncology, Inc. (CSBR) - corporate logo

Champions Oncology (CSBR) delegates drug manufacturing and testing to external contractors, maintaining its status as a compact scientific team. This chart of market price action based on the EV/EBITDA metric reflects 200.33. The business relies on unique biological samples for the R&D sector, ensuring a steady cash flow, while demand for precision preclinical diagnostics continues to grow steadily.

CSBR Champions Oncology, Inc.: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/15/2026

Summary analytical data breakdowns for Champions Oncology, Inc. (CSBR)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Summary company analysis:Champions Oncology CSBR
Product sample of championsoncology.com

For Champions Oncology (CSBR), which relies on the trust of pharmaceutical behemoths in personalized therapy, the Enterprise Value to EBITDA ratio serves as an indicator of how effectively its unique research models are capitalized. This metric correlates the market price of the business with operating profit before depreciation and taxes, allowing investors to objectively assess the real value of assets relative to their ability to act as a cash generator.

Competitors of Champions Oncology

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara Therapeutics (TARA)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (aadibio.com)|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan)|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple